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Introduction
Type 2 diabetes mellitus (T2DM) is a growing public health
and policy concern. Management of diabetes and its complica-
tions are responsible for a disproportionate amount of health-
care costs in the USA, and the prevalence of diabetes is on the
rise due to the ageing and increasing average weight of the US
population [1–3]. As a result, diabetes has been a major target
area for disease management programmes, ranging from the
development and dissemination of treatment guidelines to
algorithm-based case management [4–8].
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Abstract
Aims To evaluate barriers to following dietary recommendations in patients
with Type 2 diabetes.
Methods We conducted focus groups and surveys in urban and suburban VA
and academic medical centres. For the written survey, a self-administered ques-
tionnaire was mailed to a random sample of 446 patients with diabetes. For the
focus groups, six groups of patients with diabetes (three urban, three suburban)
were conducted, with 6–12 participants in each group. The focus groups ex-
plored barriers across various types of diabetes self-management; we extracted
all comments relevant to barriers that limited patients’ ability to follow a recom-
mended diet.
Results The written survey measured the burden of diabetes therapies (on a
seven-point rating scale). Moderate diet was seen as a greater burden than oral
agents (median 1 vs. 0, P = 0.001), but less of a burden than insulin (median 1
vs. 4, P < 0.001). A strict diet aimed at weight loss was rated as being similarly
burdensome to insulin (median 4 vs. 4, P = NS). Despite this, self-reported ad-
herence was much higher for both pills and insulin than it was for a moderate
diet. In the focus groups, the most commonly identified barrier was the cost (14/
14 reviews), followed by small portion sizes (13/14 reviews), support and family
issues (13/14 reviews), and quality of life and lifestyle issues (12/14 reviews).
Patients in the urban site, who were predominantly African-American, noted
greater difficulties communicating with their provider about diet and social cir-
cumstances, and also that the rigid schedule of a diabetes diet was problematic.
Conclusions Barriers to adherence to dietary therapies are numerous, but
some, such as cost, and in the urban setting, communication with providers, are
potentially remediable. Interventions aimed at improving patients’ ability to
modify their diet need to specifically address these areas. Furthermore, treat-
ment guidelines need to consider patients’ preferences and barriers when setting
goals for treatment.
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Although medical management is extremely important,
self-management is also a major factor in caring for Type 2
diabetes [9]. Many diabetes treatments have met with limited
success in general practice and often require patient willing-
ness to collaborate with difficult lifestyle changes. However,
despite the crucial importance of adherence to prescribed
therapy as part of self-management, there is surprisingly little
information on patients’ views of and preferences for different
therapies.
Dietary modification is a good example. Dietary recommen-
dations often require patients to alter behaviours that have
been present for a lifetime, and are based upon strong and
entrenched preferences. Regardless, diet is considered a cor-
nerstone for management of Type 2 diabetes and is usually
proposed as first-line therapy [10], though it is temporary in
most patients [11,12]. This is unfortunate, as the potential
benefits of diet are great: weight loss through proper diet and
exercise results in improved glycaemic control and possibly
reductions in cardiovascular risk and overall mortality [13–
16]. Although long-term studies of patients with diabetes have
failed to demonstrate sustained weight loss or glycaemic
improvements with dietary changes alone [12], few studies
have examined the reasons for this failure or how patients view
dietary restrictions. We undertook a study designed to evalu-
ate, both quantitatively and qualitatively, barriers to patients’
ability to follow self-management recommendations in Type 2
diabetes; this study focuses on barriers to following a pre-
scribed diet.
Methods
Patients were recruited occurred from the primary care popula-
tion of a large academic medical centre and two VA hospitals.
Patients at these facilities were identified as having diabetes
using a previously validated algorithm that used either medical
systems diagnosis information (for the academic medical centre)
or both diagnosis and pharmacy database information [17–19].
They were classified by searching for either a diagnosis of diabetes
or prescriptions for oral hypoglycaemic agents, insulin, or
glucose monitoring supplies.
The study was conducted in two phases and was approved by
the Institutional Review Board (IRB) at each study site. A quan-
titative survey phase was conducted to determine comparative
views of diabetes treatments, and a qualitative phase was con-
ducted to explore patients’ views of treatments. For the quanti-
tative phase, a mailed, self-administered 50-question survey
was sent to a random sample determined to be eligible through
the algorithm above. The survey was conducted anonymously,
and informed consent was thus waived by the IRB at both study
sites. Patients were excluded from the analysis if they were
diagnosed prior to the age of 30 (to minimize the participation of
those with Type 1 diabetes). The survey was designed to obtain
overall ratings of patient attitudes towards various hypoglycaemic
treatments, including different intensities of diet, along with
ratings of interventions on specific subscales (pain and interference
with usual daily activities). In addition, demographic informa-
tion, experience with treatments, physician recommendations
for treatments, and self-reported adherence to treatment (using
a seven-point scale with 1 = always followed, 4 = followed
about half the time, and 7 = never followed) were collected. The
validity of the measures was tested through examining whether
within-subject comparisons followed logical orders; e.g. was
twice-daily insulin consistently viewed as more burdensome
than once-daily insulin. We found that in 97% of subjects, the
ordering was consistent, and the overall ratings followed a sim-
ilarly consistent ordering. There are no clear external measures
that would serve to test the validity of the questions; indeed, in
the case of a straightforward rating of burden measured directly
from the patients, comparison with other measures is probably
of limited utility. We tested for the internal consistency reliabil-
ity of overall ratings of burden with the ratings for pain and
interference with usual activity. Cronbach’s α across these
scales ranged from 0.74 for urine testing to 0.88 for insulin
twice a day.
Demographic and clinical information was collected via
previously validated measures from the Type 2 diabetes Patient
Outcomes Research Team [19]. This included data on diabetes
treatments and duration, level of complications, provider type
and frequency of visits, income, ethnicity, and education.
Because of non-normal distributions of ratings of treatments,
simple comparisons between ratings for various hypoglycaemic
interventions were analysed using the non-parametric Wilcoxon
sign-rank test for paired comparisons. Categorical variables
were compared using contingency tables and χ2 tests of inde-
pendence. Because of non-normality and heteroscedasticity of
residuals, we conducted multivariate analyses using linear
regression with robust Huber/White sandwich estimators of
variance [20,21]. Results of all analyses were considered
statistically significant at a P-value of < 0.05.
In the qualitative phase of the study, patients with diabetes
were recruited to one of several focus groups. Recruitment was
done via flyers posted in the waiting rooms at clinic sites. All
focus group participants provided signed informed consent.
The primary goals of the focus groups were to have patients
express their views towards various aspects of diabetes care and
to provide insight into barriers to their ability to follow recom-
mended interventions. This phase was designed to complement
the survey and provide a deeper understanding of some of the
findings from the quantitative phase. A series of prescripted
questions were used to guide the groups and to open the discus-
sion (Table 1). The focus groups were led by a facilitator who
had familiarity both with diabetes care and with moderating
focus groups. In total, six focus groups were conducted, with
6–12 participants in each. This number of participants is gener-
ally big enough to generate a broad range of ideas but small
enough to allow active participation from all members [22].
The participants for the first three focus groups were recruited
from a suburban setting (Ann Arbor, Michigan); most partici-
pants were white. The remaining three focus groups were
conducted in an urban setting (Detroit, Michigan); most were
African-American. The average duration of each focus group
was 2 h; patients were provided with a £14 ($25) incentive
payment to participate.
Each focus group was audiotaped and professionally tran-
scribed. The transcripts were reviewed by a panel of investiga-
tors and statements were coded based upon their content (e.g.
related to diet, insulin therapy, or oral agents) using Q.S.R.
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NUD*ISTTM qualitative analysis software (N5 qualitative data
analysis program; Melbourne, Australia; QSR International
Pty Ltd. Version 5.0, 2000). The portions of the transcripts that
were related to diet were compiled, and the statements reviewed
by seven experts in diabetes care; these experts spanned a range
of disciplines, including medicine, public health, anthropology,
nursing, and education. The experts were asked to identify con-
tent areas that reflected major barriers or concerns that patients
had regarding their ability to comply with a diabetes diet. These
content areas were then independently reviewed by three of the
authors (N.S.S., J.T.F., S.S.). These authors then met, and
differences and overlap in categories were resolved through
consensus; there were no disputed areas after discussion. This
process led to identification of 12 major barriers to following
recommendations for diet. The content areas indicated by the
diabetes experts were tabulated, and statements that typified
each area were identified in the transcripts. The analyses of
these results were conducted as a whole and stratified by site.
Results
The written survey was mailed to a total of 446 patients, of
whom 365 were eligible (of the 81 ineligible subjects, 23 did
not have diabetes; 32 were under the age of 30 at diagnosis; 17
addresses were incorrect; and nine were deceased). A total of
197 completed surveys were returned, for a response rate of
54%. The demographics of the population that completed the
written survey are presented in Table 2. Analyses of adminis-
trative data showed that non-respondents were similar in age,
gender and insurance status to respondents.
Ratings of the burden of diet, oral agents, and insulin were
collected by asking patients to rate, on a seven-point scale
(from 0 = do not dislike at all to 6 = dislike very much) their
dislike of treatments. Subjects rated even a moderate diet (a
diet with sugar and fat reduction, but minimal calorie reduction)
as more burdensome than pills (median burden for diet = 1;
IQ range 0–3; median burden for pills = 0, IQ range = 0–1,
P = 0.001), but substantially less burdensome than twice-daily
insulin injections (median burden for insulin = 4, IQ range =
2–6, P < 0.001). However, a strict diet (a diet with sugar, fat,
and calorie reduction aimed at weight loss) was rated as simi-
lar to twice-daily insulin injections (median burden = 4, IQ
range = 2–6, P = 0.351). The results for ratings of physical
pain and interference with usual activities followed similar
patterns. Subjects found any treatments that required strict
timing of meals burdensome, with a median rating of 4, IQ
range 1–6.
We compared the ratings of the burdens of dietary therapy
across various demographic groups using robust linear regres-
sion. In multivariate analyses, the burden of moderate diet was
significantly related to age, with older patients viewing diet as
less burdensome than younger patients (for every 10 years
older, burden was less by 0.5 on the seven-point scale;
P = 0.008). Additionally, the burden of diet was viewed as
higher in subjects who had frequent visits to a dietitian (for
each visit, burden increased by 0.07 on the seven-point scale;
P = 0.029). Caucasian and African-American respondents had
similar ratings of dietary restriction; other races were not
examined due to small sample sizes. Other variables, including
demographics (gender, income and education), along with
specific characteristics (duration of diabetes, household support,
attendance at diabetes education classes) were not significantly
associated with ratings of the burden of a moderate diet.
Patients were also asked to rate, on a seven-point scale,
how closely they followed recommendations for prescribed
Table 1 Sample focus group questions
 
1 Please briefly introduce yourself and tell us a little bit about your diabetes, that is, how long have you had diabetes and how is it treated?
2 Patients do not always do everything their doctors recommend. Are there things that your doctor has recommended for you but you don’t do? Why?
3 What do you do that your doctor has recommended? Why do you do it?
4 What are the main problems you have with the treatment you are currently taking, for example, if you are currently taking insulin injections, what 
are the main problems you have with taking insulin?
5 Are there any particular issues involved in taking your treatment that causesyou difficulty or really irritate you?
6 Are there any specific events or times when taking your treatment is most bothersome, for example, during holidays or during vacations or trips?
7 Do you feel as if you had a choice about the treatment you are taking for your diabetes?
8 If you did have a choice, what factors influenced your decision to take the diabetes treatment you are currently using?
9 In what ways does your family help you administer your treatment for diabetes?
10 In what ways do they not support you or obstruct your efforts to control your blood sugar? 
Table 2 Characteristics of survey participants (n = 197)
 
Age, years (mean ± SD) 62.1 ± 11.2
Male/female, % 67/33
Median education 13 years (1 year of college)






Home glucose monitoring, % 72.6
Moderate diet, % 80.9
(avoidance of sugar and fat)
Strict diet, % 34.0
(aimed at weight loss)
Oral agents, % 55.6
Insulin, % 32.5
Average diabetes duration, years 10.5 ± 8.6
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therapies. Despite rating diet as less burdensome than insulin,
patients were much less likely to report following a diet than
taking insulin as prescribed; patients reported following their
diet somewhat more than half the time, but always or almost
always followed insulin prescriptions (mean rating for diet vs.
insulin = 3.2 vs. 1.2, P < 0.001). Patients were also less likely
to follow their diet than take oral agents (mean rating = 3.2 vs.
1.3, P < 0.001), but rated following recommendations for
oral agents and insulin similarly (mean rating = 1.3 vs. 1.2,
P = 0.36).
Focus groups
In the qualitative component of the study, we sought to under-
stand specific barriers to following suggested therapy. We
convened six focus groups at two sites. The average age of the
focus group participants was 61 years; 97% were men; and
73% had a high-school education or less. In the suburban site,
the focus groups were 88% white; in the urban site, the focus
groups were 92% African-American. The specific categories of
barriers that were identified by the reviewers of the focus
group transcripts are outlined in Table 3. The most commonly
cited problem was the cost of complying with the diet pre-
scribed for control of Type 2 diabetes. In fact, in reviewing the
transcripts, every reviewer identified cost as one of the major
concerns of the focus group participants. As most would
expect, portion size was frequently mentioned as a limiting
factor; patients often felt hungry when complying with pre-
scribed diets. Social and family support was identified as a key
area as well; lack of family support was cited as a major factor
in difficulty with maintaining diet, while those with strong
family support found it easier to adhere to dietary recommen-
dations. Other major topic areas identified by the reviewers
were the effect of diet on quality of life; confusion over the
proper elements of a diabetes diet; difficulty during holidays/
social occasions; emotional aspects of having to follow the
diet; a dislike of the food in the diet; and difficulties with the
rigid schedule associated with diabetes diet. Representative
quotes from the focus group participants are included in
Table 4.
The focus group reviewers also evaluated the groups from
the suburban (Ann Arbor) and urban (Detroit) site separately.
The comparisons between the scoring at each site are shown in
Table 5. The primary issue of concern at both sites was the
expense of the diet; portion size, quality of life, and family sup-
port were also noted as barriers at both sites. However, there
were areas that differed substantially between sites, most nota-
bly the issue of communication with health professionals,
which was a major concern at the urban, but not at the subur-
ban site. Of note, the population at the urban site was predom-
inantly African-American, which may have contributed to this
difference. Representative quotes include ‘The only thing I got
to say about the diet thing is that when you go to a nutritionist,
I have not a clue of what they are talking about’. ‘You are talk-
ing to me and you don’t know what my economical position,
my economics position, is. You don’t know how I am situated.
You don’t know the community that I live in, but you are talk-
ing to me like I am Richie Cunningham of Happy Days and
that is the problem that I have with the doctor.’ ‘You don’t
take into consideration how much money is available to me,
the community that I live in, and the sources, my resources,
that is available to me.’ ‘See, that is where it comes down to
these doctors again. They don’t understand the community or
your upbringing … It ain’t got nothing to do with black or
white. I am a southerner man. They cook like this all the time.’
Similarly, a rigid schedule was felt to be a major barrier in the
urban group, but not in the suburban group.
Discussion
Although dietary modification is considered by many to be the
first step in the treatment of Type 2 diabetes, most studies
show that the effectiveness of diet is limited and generally
non-sustainable. However, there is little information about the
specific barriers to following the typically prescribed diet.
Many providers see lack of ability to follow a diet as a simple
failure of patients’ willpower or unwillingness to change long-
standing behavioural patterns.
The results from our written survey suggest that patients
find even moderate dietary modification to be more cumber-
some than taking oral agents; a stricter diet that promotes
weight loss (and would be likely to lead to more substantial
benefits) is seen as having a burden similar to that of twice-
daily insulin injections. While it is not surprising that patients
cooperate less with diet than pills given the perceived burden
of therapy, they may be less likely to comply with diet than
with twice a day insulin injections, given similar views of the
burden of therapy. In general, patients appeared to be more
likely to cooperate with pharmaceutical diabetes management
than with self-care behaviours such as dietary modification or
home glucose monitoring.






Quality of life/ lifestyle 12
Confusion 10
Difficulty during holidays and special occasions 8
Emotional aspects 8
Good food/bad food 8
Rigid schedule 8
Communication with health professionals 7
Hypoglycaemia 4
Craving 3
*Reviewers had a broad range of expertise and independently evaluated 
the transcripts for content.
†Score range: 1 (concern identified by one reviewer at one site) to 14 
(concern identified by all reviewers at both sites).
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The focus group results of our study are particularly reveal-
ing, and help to illuminate the barriers, beyond simple dislike,
that make it difficult for patients to undertake dietary recom-
mendations. The cost of a diabetes diet was a barrier that was
mentioned by every expert who reviewed the focus group tran-
scripts. This is an important finding since minorities and those
with lower incomes bear a disproportionate burden of both
the prevalence and the complications of Type 2 diabetes [3,23–
25]. Providers, dietitians, and educators need to acknowledge
this factor when prescribing a diabetes diet; educational mate-
rial should focus not only on ways to manage diet properly,
but also on ways to do so economically. Some of the other bar-
riers mentioned by patients were expected; limited portions, a
decrease in quality of life, a lack of family support, dislike of
the foods in the diet, and difficulty during holidays and special
occasions were all mentioned as important factors. However,
patients did not mention a craving for certain foods as a
frequent problem.
Another issue that deserves special attention is the vari-
ation in patients’ perceptions of communication with health
professionals. A finding of our focus groups is that patients in
the urban setting (a group that was almost exclusively made up
of African-Americans; only one participant was not African-
American) felt that communication with their providers was a
major barrier to following recommendations for dietary mod-
ification. Quotes from the focus group participants strongly
suggest a perception that providers are unaware of cultural dif-
ferences that play a very important role in patients’ willingness
or ability to comply with prescribed therapy. Improving pro-
viders’ understanding of these critical issues must be an area of
Table 4 Sample patient quotes about barriers to following a prescribed diet
 
Cost of therapy
‘What they tell you to eat, the stuff that you are supposed to eat that is good for you, most people cannot afford’
‘I get $700 a month. After rent and all, I can’t afford to buy the vegetables and some of the things that they are talking about buying’
‘My wife and I went down and did an inventory of what it would cost to get the dietetic food … we spend about $250 a month now for food for the 
wife and I. It would have been $450 the other way … so we have to buy the cheap stuff’
Portion size
‘You couldn’t live on that diet … you have to eat twice as much as they want you to eat’
‘The little bit they want you to eat is not enough. I mean my grandkids eat more than that’
‘… you are only supposed to have three ounces of meat a day, or was it four? I forget, but all it amounts to is a little piece of meat like this. That is 
what make makes dieting so hard’
Social / family support
‘You can’t go over to one sister’s house without going over to your baby sister’s house, and you are going to eat something. They make you eat’
‘Mine are really supportive but it is really their attitude. Like I am a biting dog. Don’t get near that, he can’t have that, you know’
‘I don’t know if my wife helps me or not. She came home last night with a chocolate cake and says, you can’t have any … last week, though, she was 
good. She only bought one peach pie and one pumpkin pie’
Quality of life/ lifestyle
‘I’m not going to sacrifice everything, what do you want to be a real old man and you can’t eat, what the hell, you got to have something in life’
‘I feel deprived, I guess is what it is … I have a tendency to cheat and then I feel bad that I did that’
‘If I’m going to be alive today, I am going to eat what I want. Otherwise, there is no sense in being here, if you can’t enjoy something about it’
Confusion
‘They tell me that I’m supposed to have so many portions of this and so many portions of that. … I have not a clue what portions mean’
‘One ounce of this and a half teaspoon of that, 2 g of this, I mean it’s crazy … it confuses you too’
‘They put me on diets that I try to follow with, but it is hard and expensive. It is hard … it is really confusing a lot of the times’
Difficulty during holidays/special occasions
‘Holidays are a bad time; I mean summertime, all the time … in summertime, that cold beer tastes good, that you can’t have’
‘Thanksgiving and Christmas, the 4th of July, any holiday, because of the barbecue sauce and the sweet potato pies’
‘I find the hardest time is this time of year, Thanksgiving and Christmas’








Portion size 6 7
Support/family 6 7
Quality of life/ lifestyle 6 6
Confusion 6 4
Emotional aspects 5 3
Good food/bad food 4 4
Difficulty during holidays and 
special occasions
3 5
Rigid schedule 2 6





*Reviewers had a broad range of expertise and independently evaluated 
the transcripts for content.
†Score range: 1 (concern identified by one reviewer) to 7 (concern 
identified by all reviewers).
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emphasis if we are to design programmes to reduce many of
the inequities that are seen in diabetes outcomes.
This study has several limitations. First, it was conducted in
selected populations, and thus does not adequately represent
a true cross-section of all patients with diabetes. We sought,
however, to test a range of participants, including suburban
and urban groups. We used flyers and offered a financial
incentive to patients, which can produce a recruitment bias.
Since the focus groups were conducted in a VA sample, which
is a lower income group, they may lead to an overemphasis on
cost; however, the burden of diabetes is disproportionately
borne by those with lower socioeconomic status and in minor-
ity groups. Thus, many of the main lessons about cost and
cultural barriers to dietary adherence are likely to apply in
many locales. Second, the written survey had a response rate of
only 54%. Third, because this is a cross-sectional analysis, the
direction of causality cannot be determined for some associ-
ations; for example, the finding that patients who have more
visits to a dietitian find diet to be more burdensome may be due
either to an effect of visit frequency on perceived burden (e.g.
diet is judged burdensome because so many dietitian visits are
required with it, and in these health systems, a separate visit is
often required) or to an effect of diet burden on dietitian visit
frequency (e.g. diet burden leads to decreased ability to follow
the diet which requires more frequent dietitian visits).
While the findings of this study are important for clinical care,
they also have important policy implications. Clinical practice
guidelines are set up to standardize care as much as possible,
yet they often ignore patients’ preferences and cultural, racial,
or economic variation that may make following treatment
recommendations difficult or impossible. Continuing research
into these topics is needed to produce guidelines that meet the
needs of patients rather than those of healthcare systems. Policy
research also needs to consider these findings carefully. For exam-
ple, the cost of a diabetes diet is invisible to the healthcare system,
yet it is a very real and substantial cost that is borne by patients.
Our focus group participants also mentioned that they feel a
decreased quality of life when following a diabetes diet. While
we did not specifically quantify quality of life, the cost increment
and the quality of life decrement should both be considered
when trying to set diabetes policy and practice standards.
The burden that treatments for diabetes place on patients
is substantial. Understanding the burden of therapy and the
barriers to following recommended therapy will allow us to
design better treatment programmes and guidelines more con-
sistent with patients’ desires and values. Compromise is often
required in life, and programs that consider both burden and
benefit are those that are most likely to be successful in
improving the lives of patients, both in the short and long term.
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